tiprankstipranks
Trending News
More News >
Stride (LRN)
NYSE:LRN

Stride (LRN) AI Stock Analysis

Compare
1,039 Followers

Top Page

LRN

Stride

(NYSE:LRN)

Select Model
Select Model
Select Model
Outperform 76 (OpenAI - 5.2)
Rating:76Outperform
Price Target:
$94.00
▲(8.60% Upside)
The score is driven primarily by strong financial performance (material margin expansion, higher ROE, and improving leverage), tempered by slowing recent growth and weaker TTM free cash flow. Technicals are mixed with an overbought near-term setup and the price still below longer-term moving averages. Valuation is supportive at a 12.6 P/E, while the latest call was constructive but highlighted competitive and macro/FX risks.
Positive Factors
Enrollment-driven revenue growth
Consistent enrollment growth, especially a 17.6% rise in Career Learning, strengthens Stride's recurring tuition base and diversifies demand. Higher career enrollments and rising per-enrollment revenue in that segment support more predictable, scalable revenue and long-term program expansion.
Strong, durable margins and ROE
Sustained high gross and EBITDA margins and strong ROE indicate efficient operations and pricing power from proprietary curriculum and platform scale. These margin levels provide long-term flexibility to fund content, tech investments and withstand competitive pressures without sacrificing profitability.
Conservative leverage and healthy cash conversion
Low leverage and strong operating cash conversion support financial resilience and optionality for growth investment or shareholder returns. A conservative balance sheet reduces refinancing risk, helps absorb cyclical enrollment swings, and underpins multi-year strategic investments in products and markets.
Negative Factors
Reliance on enrollment-linked public funding
Dependence on government and district funding tied to enrollment and performance creates structural exposure to policy changes, budget cycles, and enrollment volatility. That linkage makes revenues lumpy and sensitive to regulatory shifts and funding decisions over the medium term.
ARPU compression in General Education
Falling revenue per enrollment in core general education signals pricing or mix pressure that can erode unit economics over time. If sustained, lower ARPU requires either higher enrollment growth or continued cost efficiencies to maintain margins, challenging long-term margin sustainability.
Declining free cash flow growth
A near-term drop in free cash flow growth may constrain the firm's ability to fund new product development, maintain content investment, or sustain aggressive capital returns. Persistently slowing FCF growth reduces strategic flexibility and increases sensitivity to adverse enrollment or funding shocks.

Stride (LRN) vs. SPDR S&P 500 ETF (SPY)

Stride Business Overview & Revenue Model

Company DescriptionStride, Inc., a technology-based education service company, provides proprietary and third-party online curriculum, software systems, and educational services to facilitate individualized learning for students primarily in kindergarten through 12th grade (K-12) in the United States and internationally. Its technology-based products and services enable clients to attract, enroll, educate, track progress, and support students. The company offers integrated package of systems, services, products, and professional expertise to support a virtual or blended public school; individual online courses and supplemental educational products; and products and services for the general education market focused on subjects, including math, English, science, and history for kindergarten through twelfth grade students. It also provides career learning products and services that are focused on developing skills to enter in industries, including information technology, health care, and business; and focused post-secondary career learning programs, which include skills training for software engineering, healthcare, and medical fields to adult learners under Galvanize, Tech Elevator, and MedCerts brand names, as well as provides staffing and talent development services to employers. Stride, Inc. serves public and private schools, school districts, charter boards, consumers, employers, and government agencies. The company was formerly known as K12 Inc. and changed its name to Stride, Inc. in December 2020. Stride, Inc. was founded in 2000 and is headquartered in Reston, Virginia.
How the Company Makes MoneyStride generates revenue primarily through tuition fees collected from students enrolled in its online schools. These fees vary based on the specific programs and services offered. Additionally, the company earns revenue from the sale of its proprietary curriculum and educational resources to other schools and educational institutions. Stride also partners with various school districts and state education agencies, often receiving government funding based on enrollment numbers and student performance metrics. This diversified revenue model, combined with strategic partnerships and collaborations, contributes significantly to the company's overall financial performance.

Stride Earnings Call Summary

Earnings Call Date:Jan 27, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call presented a strong operational and financial performance with meaningful margin expansion, record quarterly operational PAT, robust cash conversion and disciplined capital allocation. These positives were balanced by sector realities: US competitive pressures, selective product exits to protect margins, donor-dependent access markets with lumpy demand, forex headwinds and the early-stage nature of new growth initiatives (controlled substances, Beyond Generics). Overall, the discussion emphasized sustainable, profitability‑led growth with cautious optimism on medium‑term market expansion.
Q2-2026 Updates
Positive Updates
Revenue Growth
Quarter revenue grew 4.6% year‑on‑year; first half revenue grew ~5.5% YoY. US revenue was $73M, up ~2% YoY.
Strong EBITDA Performance
Quarterly EBITDA of Rs 232 crore with a 19% margin, representing ~25% YoY EBITDA growth; H1 EBITDA Rs 450 crore with a 19.2% margin and margin expansion of ~320 bps in Q2.
Remarkable Operational PAT and EPS
Highest ever quarterly operational PAT of Rs 140 crore and operational EPS of Rs 15.2. H1 operational PAT Rs 154 crore (operational EPS Rs 27.6). Management cited operational PAT growth of ~84% YoY for the quarter.
Gross Margin Expansion
Management reported significant gross margin improvement: quarter gross margin quoted at ~57.8% (up ~500 bps YoY) and H1 gross margin ~59% (up ~410 bps YoY).
Cash Generation and Deleveraging
Operational cash of Rs 394 crore for H1 (~87% conversion of EBITDA to operational cash); free cash flow of Rs 73 crore used for debt reduction. Net debt reduced by Rs 73 crore to Rs 1,449 crore and EBITDA-to-net-debt improved to 1.65x from 1.9x.
Pipeline and Product Footprint
Pipeline strength: 230+ ANDAs filed and 215+ ANDAs approved; 70 commercialized products with top-3 ranking in 37 products (these top products contribute ~75% of US revenue). Three new product launches in H1.
Geographic Diversification and Growth Markets
Rest-of-world (other regulated + growth markets) registered ~14% growth (other regulated markets ~16% YoY). Growth markets revenue was $17M, up ~7% YoY; management highlighted crossing a key threshold in these markets (~Rs 1,030 crore stated) and expects accelerated growth going forward.
Capital Allocation Discipline and Investment
CapEx of Rs 149 crore in H1 (maintenance + growth). R&D guidance reiterated at roughly $15–20M (management committed to higher R&D, including nasal/Beyond Generics programs). Maintenance CapEx guidance ~Rs 100–150 crore per year.
Improved Finance Costs and Efficiency Metrics
Net finance cost for H1 at Rs 61 crore versus Rs 105 crore last year (noting a quarter finance income reduced net cost). Cash-to-cash cycle steady at 113 days (improved 3 days QoQ). ROCE improved to 16% from 14.9%.
Negative Updates
US Competitive Pressure and Relative Flatness
US segment has been broadly flat for several quarters with intense competition in certain molecules; management noted selective pricing pressure and a calibrated, profitability-first launch approach rather than chasing volume.
Product Exits and Profitability Filtering
Management disclosed dropping several products from commercialization because they did not meet profitability thresholds, indicating near-term revenue tradeoffs to protect margins.
Access Markets: Lumpy Demand and Donor Funding Risk
Access markets remain lumpy with donor funding uncertainty; management expects H2 may be slightly better but flagged reliance on donor agency decisions and opportunistic revenue timing.
Forex Impact on Net Debt
Adverse forex revaluation impacted net debt by ~Rs 71 crore; although net debt fell overall, currency movement remains a risk to balance sheet metrics.
One‑offs and Reported PAT vs Operational PAT
Reported PAT (quarter Rs 132 crore; H1 Rs 137 crore) was lower than operational PAT due to exceptional one‑off expenses—these items reduced reported profitability versus operational metrics.
Controlled Substances and Beyond‑Generics Still Early
Controlled substances and Beyond‑Generics initiatives are nascent: initial filings/launches done but material revenue impact expected primarily from next year onward—near‑term contribution is limited and timing depends on quotas and regulatory steps.
Ongoing Uncertainties: Tariff and External Risks
Management noted external risks such as potential tariff developments and market dynamics; while no immediate tariff impact was reported, they continue to monitor evolving external policy risk.
Company Guidance
Guidance from the call emphasized long‑term, sustainable growth with EPS accretion: management reiterated a US revenue target of $400m by FY28 and said the “rest of world” (other regulated + growth, net of access) should be able to mirror the US in ~2–3 years after recent momentum (rest‑of‑world crossed ~₹1,030 crore and is growing ~14–16% YoY; US was ~$73m, +2% YoY), and that controlled‑substances activity should meaningfuly contribute from next year. Financial guidance/targets and run‑rates called out include sustaining gross margins in the ~57–59% range, EBITDA margin ~19% (Q2 EBITDA ₹232 crore; H1 EBITDA ₹450 crore), operational PAT record of ₹140 crore in Q2 (H1 operational PAT ₹154 crore; operational EPS Q2 ₹15.2, H1 ₹27.6), revenue growth of 4.6% in Q2 (5.5% H1), R&D budget of about $15–20m, maintenance CapEx of ~₹100–150 crore (H1 CapEx ₹149 crore), tax rate (ETR) ~15–20% for the year, strong cash conversion (operational cash ₹394 crore in H1, ~87% of EBITDA, free cash ₹73 crore used to cut debt), net debt ~₹1,449 crore (FX restatement hit ~₹71 crore) with EBITDA/net‑debt ~1.65x (improving from 1.9x), ROCE ~16% and cash‑to‑cash ~113 days; management expects H2 to be at least slightly stronger and to continue prioritizing profitable launches and capital discipline.

Stride Financial Statement Overview

Summary
Strong multi-year profitability and margin expansion with improving ROE and declining leverage support a high score. Offsets are the sharp slowdown in recent revenue growth and a notable TTM free-cash-flow drop, which raises durability concerns.
Income Statement
86
Very Positive
LRN shows a strong multi-year earnings expansion with clear margin improvement. Revenue rose from $1.54B (2021) to $2.41B (2025 annual) and $2.52B in TTM (Trailing-Twelve-Months), while net margin improved from ~4.6% (2021) to ~12.0% (2025 annual) and ~12.8% in TTM. Operating profitability strengthened as well, with EBIT margin rising from ~7.2% (2021) to ~16.4% (2025 annual) and ~17.8% in TTM. The main drawback is the sharp deceleration in growth in the latest period (TTM revenue growth of ~1.8% versus higher growth rates in prior years), which may pressure future operating leverage if it persists.
Balance Sheet
83
Very Positive
The balance sheet appears healthy with moderate leverage and improving capital structure. Debt relative to equity declined meaningfully over time (from ~0.70 in 2022 to ~0.37 in 2025 annual; ~0.38 in TTM), alongside rising equity ($805M in 2021 to ~$1.55B in TTM). Returns to shareholders are strong and improving (return on equity ~8.9% in 2021 to ~19.5% in 2025 annual and ~22.0% in TTM). A remaining watch item is that total debt remains sizable in absolute terms (~$556M TTM), which can still constrain flexibility if operating momentum slows.
Cash Flow
72
Positive
Cash generation is solid and generally supportive of reported earnings, with free cash flow close to net income (free cash flow to net income ~1.00 in 2025 annual and ~0.96 in TTM). Operating cash flow also covers net income well (about 1.43x in 2025 annual and ~1.56x in TTM), indicating good cash conversion recently. The key weakness is volatility: free cash flow declined sharply in the latest TTM period (free cash flow growth of about -37%), even though profitability improved, which raises questions about working-capital timing or reinvestment needs.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.41B2.04B1.84B1.69B1.54B
Gross Profit943.92M763.60M647.07M596.48M534.90M
EBITDA508.39M386.18M291.31M253.26M203.36M
Net Income287.94M204.18M126.87M107.13M71.45M
Balance Sheet
Total Assets2.29B1.92B1.76B1.64B1.58B
Cash, Cash Equivalents and Short-Term Investments985.27M692.29M522.73M389.40M386.08M
Total Debt549.76M528.21M543.81M565.67M466.28M
Total Liabilities814.34M744.44M813.37M830.96M772.65M
Stockholders Equity1.48B1.18B947.30M812.58M804.65M
Cash Flow
Free Cash Flow372.81M217.21M136.60M139.26M81.89M
Operating Cash Flow432.82M278.80M203.15M206.88M134.15M
Investing Cash Flow-88.00M-139.87M-118.24M-110.76M-165.44M
Financing Cash Flow-62.94M-49.12M-63.50M-93.31M204.58M

Stride Technical Analysis

Technical Analysis Sentiment
Positive
Last Price86.56
Price Trends
50DMA
67.76
Positive
100DMA
95.39
Negative
200DMA
121.23
Negative
Market Momentum
MACD
3.89
Negative
RSI
81.34
Negative
STOCH
68.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRN, the sentiment is Positive. The current price of 86.56 is above the 20-day moving average (MA) of 73.01, above the 50-day MA of 67.76, and below the 200-day MA of 121.23, indicating a neutral trend. The MACD of 3.89 indicates Negative momentum. The RSI at 81.34 is Negative, neither overbought nor oversold. The STOCH value of 68.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LRN.

Stride Risk Analysis

Stride disclosed 45 risk factors in its most recent earnings report. Stride reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Stride Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$2.00B17.696.76%2.99%3.74%-8.40%
76
Outperform
$3.60B13.1722.26%17.25%30.15%
76
Outperform
$2.06B13.6916.14%1.88%24.23%17.56%
73
Outperform
$3.57B15.5717.92%12.24%52.97%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
$1.02B-22.00-7.43%8.10%43.35%
57
Neutral
$2.82B-26.813.19%-6.25%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LRN
Stride
86.56
-50.02
-36.62%
PRDO
Perdoceo Education
32.64
4.24
14.92%
ATGE
Adtalem Global Education
105.68
-1.92
-1.78%
STRA
Strategic Education
85.96
-11.67
-11.95%
COUR
Coursera
6.26
-1.68
-21.16%
MH
McGraw Hill, Inc.
14.59
-2.22
-13.21%

Stride Corporate Events

Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Stride’s Annual Meeting Approves Key Proposals
Neutral
Dec 10, 2025

Stride held its Annual Meeting on December 4, 2025, where several key proposals were voted on by stockholders. The election of directors saw eight nominees confirmed to continue in their roles. Additionally, the appointment of KPMG LLP as the independent auditor was ratified, executive compensation was approved on an advisory basis, and amendments to the 2016 Plan and the Employee Stock Purchase Plan (ESPP) were also approved. These decisions reflect the company’s ongoing governance and operational strategies.

The most recent analyst rating on (LRN) stock is a Buy with a $68.00 price target. To see the full list of analyst forecasts on Stride stock, see the LRN Stock Forecast page.

Stock Buyback
Stride Announces $500 Million Stock Buyback Program
Positive
Nov 3, 2025

On November 3, 2025, Stride, Inc. announced the approval of a stock repurchase program authorizing the buyback of up to $500 million of its common stock until October 31, 2026. This move reflects the company’s confidence in its long-term growth prospects and robust financial position, with the flexibility to repurchase shares depending on market conditions, aiming to create long-term value for shareholders.

The most recent analyst rating on (LRN) stock is a Hold with a $77.00 price target. To see the full list of analyst forecasts on Stride stock, see the LRN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 29, 2026